Volume 29, Number 6—June 2023
Research
Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain
Table 3
Clinical characteristics of cases without short-term SARS-CoV-2 persistence in a study of early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain*
Characteristic | Value, n = 11 |
---|---|
Average age, y (range) |
58.5 (1–94) |
Sex | |
M | 4 (36.4) |
F |
7 (63.6) |
Illness severity | |
Asymptomatic | 2 (18.2) |
Mild | 4 (36.4) |
Intermediate | 2 (18.2) |
Severe |
2 (18.2) |
Care required | |
Emergency | 1 (9.1) |
Hospital admission | 6 (54.5) |
Hospital admission for COVID-19 | 3 (27.3) |
Nosocomial transmission | 1 (9.1) |
ICU | 0 |
ICU for COVID-19 |
0 |
Underlying conditions | |
None of interest | 3 (27.3) |
High blood pressure | 6 (54.5) |
COPD | 2 (18.2) |
Asthma | 1 (9.1) |
Diabetes | 0 |
Ictus | 1 (9.1) |
Overweight/obesity | 6 (54.5) |
Heart disease | 5 (45.5) |
Autoimmune | 3 (27.3) |
Oncological | 2 (18.2) |
Chronic kidney disease | 2 (18.2) |
HIV infection | 1 (9.1) |
AIDS | 0 |
Pregnant | 0 |
Paxlovid use‡ | 1 (9.1) |
Remdesivir use | 3 (27.3) |
Tocilizumab use | 1 (9.1) |
Dexamethasone use |
4 (36.4) |
Death |
1 (9.1) |
Vaccines and serology | |
Complete vaccination schedule | 8 (72.7) |
Incomplete vaccination schedule | 1 (9.1) |
Unvaccinated | 2 (18.2) |
Previous positive serology for SARS-CoV-2 | 3 (27.3) |
Previous negative serology for SARS-CoV-2 | 2 (18.2) |
Serology not available | 6 (54.5) |
*Values are no. (%) except as indicated. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit. †Illness severity was defined according to the following criteria: mild, general unrest, cough, diarrhea, cephalgia, fever, anosmia, myalgias, rhinorrhea; moderate, previous symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; severe, previously listed symptoms plus bilateral pneumonia or severe respiratory failure. ‡Nirmatrelvir/ritonavir.
1This senior authors contributed equally to this article.
2Additional members of the Gregorio Marañón Microbiology-ID COVID-19 Study Group who contributed data are listed at the end of this article.